Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.
Scandinavian Journal of Haematology 97(1):83 (2016)
Long-term therapy with IFN-α2 is associated with sustained major molecular remissions in JAK2-positive ET and PV. The efficacy of IFN-α2 may be partly mediated by modulation of immune cells, which was investigated in twenty patients with ET (n = 6) and PV (n = 14). The frequency of CD4(+) CD25(+...
Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
New England Journal of Medicine 373(26):2579 (2015)
Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?
Gynecologic Oncology 139(2):312 (2015)
Thrombocytosis has been associated with higher stage and mortality of cancer, however, the evidence is conflicting. We examined the stage distribution and prognosis of gynecologic cancer according to levels of prediagnostic platelet count.
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
New England Journal of Medicine 372(17):1670 (2015)
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Scandinavian Journal of Haematology 94(3):227 (2015)
In recent years, major molecular remissions have been observed in patients with JAK2-positive chronic myeloproliferative neoplasms (MPNs) after therapy with IFN-α. IFN-α is known to have altering effects on immune cells involved in immune surveillance and might consequently enhance anti-tumor im...
Association of the blood eosinophil count with hematological malignancies and mortality.
American Journal of Hematology 90(3):225 (2015)
Blood eosinophilia (≥0.5 × 10(9) /l) may be an early sign of hematological malignancy. We investigated associations between levels of blood eosinophils and risks of hematological malignancies and mortality in order to provide clinically derived cut-offs for referral to specialist hematology care...
Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art.
Mediators of Inflammation 2015:964613 (2015)
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.
Scandinavian Journal of Haematology 93(3):224 (2014)
Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL-40 as a biomarker of disease burden has been demonstrated ...
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Expert Review of Hematology 7(2):203 (2014)
Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and he...
A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
Leukemia Research 38(2):263 (2014)
A novel murine model for myeloproliferative neoplasms (MPNs) generated by overexpression of the transcription factor NF-E2 has recently been described. Sustained overexpression of NF-E2 in this model induced myeloid expansion with anemia, leukocytosis and thrombocytosis. Herein, it is debated if...
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
Haematologica 99(1):e5 (2014)
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
British Journal of Haematology 163(3):393 (2013)
The impact of first-line treatment with the anti-CD 20 chimeric monoclonal antibody rituximab in patients with warm-antibody reactive autoimmune haemolytic anaemia (WAIHA) is unknown. We report the first randomized study of 64 patients with newly diagnosed WAIHA who received prednisolone and rit...
Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes.
Journal of Immunology 191(8):4059 (2013)
Activated platelets are known to modulate immune responses by secreting or shedding a range of immunomodulatory substances. We examined the influence of activated platelets on cytokine production by normal human mononuclear cells, induced by tetanus toxoid (TT), human thyroglobulin (TG), Escheri...
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
British Journal of Haematology 162(4):498 (2013)
Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator-initiated, non-randomized, open-label phase II multi-centre study included 63 patients (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primar...
The role of cytokines in the initiation and progression of myelofibrosis.
Cytokine & Growth Factor Reviews 24(2):133 (2013)
Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms. Abnormal expression and activity of a number of proinflammatory cytokines are associated with MF, in which immune dysregula...
Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.
Haematologica 95(12):2153 (2010)
Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in de novo acute myeloid leukemia, was not d...
[Aquagenic pruritus from polycythaemia vera--treatment with paroxetine, a selective serotonin reuptake inhibitor].
Ugeskrift for laeger 170(38):2981 (2008)
Pruritus is one of the most frequent and bothersome symptoms of polycythaemia vera and other chronic myeloproliferative disorders. The treatment is often difficult and ineffective. Here, we present four patients with severe pruritus, three of whom were successfully treated with paroxetin, a sele...
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Blood 112(1):141 (2008)
Activating mutations of MPL exon 10 have been described in a minority of patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET), but their prevalence and clinical significance are unclear. Here we demonstrate that MPL mutations outside exon 10 are uncommon in platelet cDN...
B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Expert Opinion in Biological Therapy 7(7):1061 (2007)
In this review, the authors summarise the clinical results obtained after therapy with rituximab in autoimmune diseases, including Graves' disease and Graves' ophthalmopathy. On the basis of qualitative and quantitative analyses of B- and T-cell subsets, and autoantibody levels obtained in other...
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
Journal of Clinical Endocrinology & Metabolism 92(5):1769 (2007)
Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of ben...